Pipeline Roivant Discovery Roivant Health Investor Relations People Join Us Contact Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies R&D Day 2021 CLICK HERE TO VIEW MORE FROM OUR R&D DAY The Vant Family IMMUNOVANT Enabling normal lives for patients with autoimmune diseases DERMAVANT Leading innovation in medical dermatology DATAVANT Organizing the world's healthcare data ARUVANT Developing gene therapies for rare diseases GENEVANT Delivering results through RNA therapeutics CYTOVANT Developing novel and innovative cellular therapeutics in Asia LOKAVANT Shifting the paradigm in clinical trial intelligence VANT.AI Expanding the boundaries of in-silico drug design PROTEOVANT Degrading errant proteins to elevate patient health KINEVANT Developing a new therapy for sarcoidosis Pipeline We have a diverse pipeline of investigational drugs across our family of companies. Company Compound Indication Modality Phase Affivant AFM32 Solid Tumors Biologic Preclinical Aruvant ARU-1801 Sickle Cell Disease Gene Therapy Phase 2 Aruvant ARU-2801 Hypophosphatasia Gene Therapy Preclinical Cytovant CVT-TCR-01 Oncologic Malignancies Cell Therapy Preclinical Dermavant Tapinarof Psoriasis Topical Registration Dermavant Tapinarof Atopic Dermatitis Topical Phase 3 Dermavant Cerdulatinib Vitiligo Topical Phase 2 Dermavant Cerdulatinib Atopic Dermatitis Topical Phase 1 Dermavant DMVT-504 Hyperhidrosis Topical Phase 1 Dermavant DMVT-503 Acne Topical Preclinical Immunovant IMVT-1401 Myasthenia Gravis Biologic Phase 2 Immunovant IMVT-1401 WAIHA Biologic Phase 2 Immunovant IMVT-1401 Thyroid Eye Disease Biologic Phase 2 Kinevant Namilumab Sarcoidosis Biologic Phase 1 Lysovant LSVT-1701 S. Aureus Bacteremia Biologic Phase 1 Discovery Roivant's drug discovery capabilities include the leading computational physics-based platform for in silico drug design and optimization as well as machine learning-based models for protein degradation. The integration of our computational and experimental engines enables the rapid design of molecules with high precision and fidelity to address challenging targets for diseases with high unmet need. Our current modalities include small molecules, heterobifunctionals and molecular glues. Learn More Roivant Health Roivant Health is our platform for founding and funding innovative digital health businesses. As an integrated pharma-tech business, we hope to lead the transition to a more data-driven, patient-centric, and value-oriented health system. Companies we have built include Datavant, now the nation's largest health data ecosystem, and Lokavant, a leading clinical trial intelligence company creating operational transparency for sponsors and CROs. People Management Vant Leadership Board Members Matthew Gline Chief Executive Officer Eric Venker, MD President & Chief Operating Officer Mayukh Sukhatme President & Chief Investment Officer Frank Torti, MD Vant Chair Richard Pulik Chief Financial Officer Rakhi Kumar Chief Accounting Officer Jo Chen General Counsel Woody Sherman, PhD Chief Computational Scientist Alex Gasner EVP, Roivant Health Select Partners Contact NEW YORK Roivant Sciences, Inc. 151 W 42nd Street 15th Floor New York, NY 10036 United States BOSTON Roivant Sciences, Inc. 451 D Street Boston, MA 02210 United States BASEL Roivant Sciences GmbH Viaduktstrasse 8 4051 Basel Switzerland CONTACT General Information Careers Investor Relations © 2021 Roivant Sciences Ltd. All rights reserved. Careers Privacy Policy